

This is where Polish
innovation begins





Our mission



We respond
to the key challenges
of modern medicine


ADAMED
For the Family

Dear Sir or Madam,

The history of Adamed is about responding to the key challenges of modern medicine. This is both our mission and the direction we have consistently taken since 1986. Every day, we work with numerous scientists on innovative research projects aimed at improving existing therapies and promoting disease prevention and a healthy lifestyle. To achieve our goals, we employ the best specialists in the country and collaborate with leading scientific centres and institutions, while employing state-of-the-art technologies in all areas of our operations.

All this makes Adamed a leader in the next-generation pharmaceutical market in Poland. Our products are available in over 70 markets all over the world. Even with this success, we have no intention of resting on our laurels. We continue to evolve and to search for inspiration and unconventional solutions.

We encourage you to learn more about Adamed Pharma – the place where Polish innovation begins.

Yours faithfully

Małgorzata Adamkiewicz, MD, PhD
President of the Supervisory Board of Adamed Pharma




History of Adamed Pharma

Adamed established
by Marian Adamkiewicz,
MD, PhD



1986

1991




Furaginum
marketed

First
manufacturing
plant opened
in Pieńków
near Warsaw



1994

1998



Authorisation obtained
for the first Polish
amlodipine – the first
product manufactured
using our patented
manufacturing process

R&D division
established




1999

2000



GMP certification
confirming our adaptation
to EU manufacturing
standards obtained

Research on innovative medicines initiated



2001

2002



Second manufacturing plant opened in Ksawerów, near Łódź

EU exports begin.
EU-wide authorisation obtained for amlodipine even before Poland's accession to the EU in 2004



2003

2005/2009



First science and industry consortium established.



Representative office in Ukraine established



Adamed Laboratorios begins sales in Spain

Acquisition of Polfa Pabianice and Agropharm



2010

2011/2012



Representative office in Russia established

 Representative office in Kazakhstan established



2013

2013/2014



State-of-the-art Research and Development Centre built

Development of AD-051.4 – an innovative anticancer molecule developed as a part of the ONCO-3CLA project – begins





2015

2016




Research and Development Centre inaugurated

  Representative offices in the Czech Republic and Slovakia established



2017





About us



Company profile

Adamed Pharma is a Polish pharmaceutical and biotechnology company manufacturing over 500 products offered to patients in over 70 countries worldwide. It currently has almost 2,700 employees. The company has been working with leading universities and research institutes and is among the ten largest pharmaceutical companies operating in Poland (source: IQVIA)



3

production plants

2 in Poland i 1 in Vietnam
over 3 billion tablets a year



Over 500

Products in our portfolio



Almost 2400

Adamed employees
in Poland
and around the world



3 research platforms

- oncology
- neuropsychiatry
- diabetology




19 therapeutic areas

- Allergology
- Angiology
- Cardiology
- Dermatology
- Diabetology
- Gastroenterology
- Gynaecology
- Internal medicine
- Laryngology
- Neurology
- Oncology
- Ophthalmology
- Orthopaedics
- Paediatrics
- Psychiatry
- Pulmonology
- Rheumatology
- Urology
- Vascular surgery

Adamed Pharma took 1st place in the Pharmaceuticals and Biotechnology category and 19th place in the full list of 300 ranking companies in the prestigious Forbes Polska Ranking: Poland's Best Employers 2023 - The Best Employers in Poland 2023.

Adamed revenue*

(EUR) € million



* Internal data.

This is where Polish innovation begins

Adamed was created basing on its own scientific ideas and its own patents. Since 2001, we have invested almost 448 M EUR in R&D activity and capital investments. In 2016, we opened a modern, 3,000 square metre R&D Centre, fully furnished with state-of-the-art research infrastructure.

In 2022, as part of its activities under the New Drug Discovery strategy, Adamed Pharma has purchased facilities with laboratory infrastructure based in Kajetany near Warsaw. Over the next two years, the site will allow the implementation of new drug development projects.



Overs 200 innovative and generics patents



88 inventions

Adamed's R&D Center has been established with the purpose of implementing research projects. These projects aim to improve the existing therapies and search for new drugs relying on organic synthesis and new technologies, and to provide support through physical and chemical analysis. The Center runs projects in the lab phase and the semi-industrial phase to enable the transfer of technologies to Adamed Pharma's manufacturing facilities. The two-storey laboratory building is equipped with a modern facility management system and number of other systems for the effective and safe operation of laboratories, including purified water and technical gas distribution systems,

local contaminated air exhaust systems, and systems for maintaining and monitoring stable climate and fire-fighting conditions.

The formulation and technology laboratory has been built as a class-D pharmaceutical facility with a higher air purity standard to accommodate the technologies being developed there.

Our experts at the research and development (R&D) labs use the latest technological advancements and modern equipment to develop both basic and more original dosage forms such as multilayer tablets, over-encapsulated tablets etc. The state-of-the-art analytical equipment available in the laboratories, such as SEM, XRPD, UPLC/MS, and expertise backed by experience place us at the forefront of the pharmaceutical companies relying on innovation in their R&D activities.

Research and Development Activities

Research and development activities in Adamed Pharma are conducted in two areas: innovative and generic. The work on interdisciplinary development projects in these areas is also supported by other teams responsible for regulatory affairs, clinical research, project management and intellectual proper-

ty protection. The generic area brings together high-level experts who introduce elements of innovation into the work on generic drugs to accommodate patients' needs. Well-equipped laboratories for organic synthesis, formulation and technology, and analytics make it possible to effectively implement even very ambitious and multi-stage research projects. Innovation Area responsible for early development of the originators (discovery, pre-clinical stage) comprises a number of closely cooperating units: Data Modelling & Analysis Lab and In Vivo Study Team. Our research department is based on three structures operating in parallel: Biotechnology Lab, Protein Biophysics Lab and Cell Biology Lab. Numerous scientists from Polish and foreign academic institutions and biotechnology companies provide a significant support to the personnel at the units specified above. The organic synthesis, analytic, legal, and tax and investment funding departments provide inhouse support within our organization.





Research platforms

Oncology platform

ONCO2 (AD-051.4)

The purpose of the project is to develop a biotechnology drug candidate, a fusion protein based on the TRAIL molecule. AD-051.4 is characterised by a dual pro-apoptotic and antiangiogenic mechanism of action, owing to which the candidate molecule has demonstrated to be highly effective in various oncological indications in in-vivo and in-vitro preclinical studies. Currently, preclinical evaluation of the molecule was completed in the project, enabling the initiation of clinical trials in cancer patients with solid tumours. The on-going production of the molecule in the clinical trial batch will make it possible to start phase I clinical trials and continue the clinical development of AD-051.4.

Project co-financed from the State budget by the Medical Research Agency, in the Competition for the Development of Targeted or Personalised Medicine Based on Cell Therapies or Protein Products.



ONCO-32 (AD-021.32)

AD-021.32 is a small-molecule anticancer compound whose mechanism of action is inhibition of Mdm2-p53 binding, reactivation of the p53 protein and induction of apoptosis of cancer cells. The clinical candidate AD-021.32 is more effective than its available competitors, as demonstrated in in-vitro studies and in in-vivo mouse xenograft studies. It is characterised by high bioavailability and its oral dosing causes a complete remission of sensitive tumour models. The molecule also exhibits synergistic effects in numerous drug combinations. The project is now at the stage of completed preclinical trials necessary for the initiation of phase 1 first-in-human (FiH) studies in cancer patients. Preparations for the initiation of the clinical trial are on-going.

The value of the project is PLN 34,749,466.78, of which PLN 18,170,000 are the funds of the National Centre for Research and Development granted under the Fast Track Programme for Mazovia for the project "Clinical development of an innovative anticancer compound relying on p53 protein activation" "MAZOWSZE/0012/19-00".

AD-061 series

The INFTRAIL project is implemented as part of a panel of proof-of-concept projects for new therapy candidates. Its purpose is to investigate the therapeutic potential and safety of biotechnological molecules which are a combination of two cytokines with pro-apoptotic and immunostimulating activities in cancer treatment. The project involves the conduct of research on the selection of safe doses as well as on the potential for immune system activation and on anticancer activity in syngenic animal models. In addition, processes for obtaining selected molecules for future production for the purposes of toxicological and clinical studies are being optimised.



Narodowe Centrum
Badań i Rozwoju

Neuropsychiatry platform

Research conducted as part of the neuropsychiatry platform is aimed at developing innovative drug candidates for the treatment of central nervous system disorders which currently pose the greatest civilization challenges, such as mood disorders, schizophrenia and Alzheimer's disease. The research is being carried out in close cooperation with leading research centers in Poland, such as the Medical College at the Jagiellonian University and the Institute of Psychiatry and Neurology in Warsaw. The key achievement of the research work carried out under the neuropsychiatry platform is the development of a drug candidate (as part of an advanced preclinical development phase) which was commercialized for a US company Acadia Pharmaceuticals in late 2020. Acadia is a pioneer in the development of antipsychotic drugs with a non-dopaminergic mechanism of action, and is responsible for further pharmaceutical development of the drug candidate as part of the collaboration. The current research activities of the neuropsychiatry platform focus on searching for innovative drug candidates for the treatment of drug-resistant depression.



SORAAD


The purpose of the project is to meet the currently most important medical needs in the pharmacotherapy of depression, such as the rapid onset of drug action, reduction of side effects and oral bioavailability. This is to be achieved through specific modulation of a combination of receptors and transporters in the central nervous system by a small molecule with advantageous physicochemical properties. The project is carried out in cooperation with our long-term academic partners from the Collegium Medicum of the Jagiellonian University.

Diabetology platform

DILOC2

The purpose of DILOC2 is to develop a medicine that would combine the convenient oral route of administration and an innovative approach to the mechanism of action, so as to fully exploit the incretin effect in the treatment of patients with obesity. Obesity is the key non-genetic risk factor for serious cardiometabolic conditions, disability or premature death. The final result of the project will be the patent-protected structure and technology of manufacture of a molecule with the characteristics that will potentially enable it to obtain the “best in class” status.

Project DILOC2 is a research and development project implemented by the Innovation Department since June 2020. Its value is over 30 million zlotys, which includes more than 19 million zlotys of funds from the National Centre for Research and Development granted under the Intelligent Development Programme.



Infectious diseases


Vaccine1

The Vaccine1 project is being implemented by a consortium involving Adamed Pharma, the University of Gdańsk and the Institute of Biochemistry and Biophysics of the Polish Academy of Sciences. The main objective of the project is to develop a recombinant mRNA/VLP-based vaccine against zoonotic pathogens that pose a threat to human health. The new mRNA/VLP-based vaccine is expected to be characterised by greater safety and to provide better protection against infection than the existing vaccines. Moreover, it should be possible to store it at 4°C without loss of quality. Adamed Pharma is the leader of the consortium and the partner responsible for delivering the technology for the manufacture of the drug candidate which will be provided by the scientific entities, and for conducting clinical trials of this medicine.

The total value of the project is over PLN 87 million, of which almost PLN 60 million is financed from the State budget by the Medical Research Agency.



Pipeline



Our science partners:

- Medical College, Jagiellonian University
- University of Gdańsk
- International Center for Cancer Vaccine Science
- Institute of Biochemistry and Biophysics, Polish Academy of Sciences in Warsaw
- Institute of Physical Chemistry, Polish Academy of Sciences in Warsaw
- Institute of Immunology and Experimental Therapy, Polish Academy of Sciences in Wrocław
- Łukasiewicz Research Network - PORT Polish Center for Technology Development
- Medical University of Warsaw
- Medical University of Gdańsk
- Professor Zygmunt Wasylewski Foundation for the Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University
- International Institute of Molecular and Cell Biology
- Institute of Industrial Organic Chemistry, Branch Office in Pszczyna
- Pharmaceutical Research Institute
- The John Paul II Catholic University in Lublin
- Institute of Pharmacology, Polish Academy of Sciences in Krakow
- University of Warsaw
- Wrocław University of Science and Technology



Instytut
Farmaceutyczny



Łukasiewicz



UNIWERSYTET
WARSZAWSKI



INSTYTUT FARMAKOLOGII
POLSKIEJ AKADEMII NAUK



Politechnika
Wroclawska



Institute of Industrial Organic Chemistry
Branch Pszczyna
POLAND


ADAMED
For the Family

Adamed's modern Production and Logistic Centre

It is also the showcase of the Łódź region and a reliable job creator employing a highly-qualified workforce. It is important to implement good practices from other sectors, where the management of the broadly understood supply chain is an important source of competitive advantage.

Early 2022 saw the completion of another stage of expansion of the Production and Logistics Centre in Pabianice, one of the most advanced facilities of this kind in the Polish pharmaceutical industry. Through the implementation of the project, we are set to improve access to medicines for patients in Poland.

By expanding the Pabianice plant, we will enhance its production capacity from 2 billion tablets (2020) to 4 billion tablets (2027) and will increase the level of automation and robotisation of processes.





Production and Logistic Centre in Poland

2 PRODUCTION SITES



2.5 tablets a year



quality & compliance



Production pillars:

cGMP RiskManagement

KAIZEN

TPM/SMED/Simple Processes



65 packages a year

6 400 batches released per year



Every year, the Centre is subject to approximately a dozen inspections and audits carried out by contractors – mostly large multinational companies.

The Centre is equipped with several dozen manufacturing and tablet packaging machines

Our competitive edge:

→ reliability

→ flexibility

**ADAMED**
For the Family

Your contract manufacturing partner

- multi-dose capsules
- tablets

Our expertise includes technology transfer and contract manufacturing of medicinal products and supplements in solid forms, such as tablets and capsules, and is backed up by an extensive list of references worldwide.

We are pleased to offer our customers versatile services tailored to their individual needs through access to our world-class facilities and high-level scientific input into each project.

We manufacture the following forms of products and intermediates:

- Hard multi-dose capsules (pellets, powder, granulations, tablets, micro-doses for inhalation products, micro-tablets, liquid forms)
- Immediate release tablets
- Controlled-release tablets
- Fast disintegrating tablets
- Film-coated tablets
- Multi-layer tablets
- Products manufactured using the direct tableting/encapsulation process
- Wet granulations (obtained using fluid methods and high shear granulator mixers)
- Dry granulations obtained by compacting (including with selective particle size distribution).

We apply cGMP production standards:

- Sourcing and qualification of manufacturers of active agents, excipients, and packaging materials
- Preparing quality documentation and releasing raw materials for production
- Mixing
- Granulation
- Compression/encapsulation
- Coating
- Blistering
- Unit packaging
- Stability testing
- Releasing for sale
- Preparation of e-CTD documentation for registration purposes
- Storing archive samples.

Multi-dose capsules

Currently available dosing systems:

micro-dosing

up to 72,000 capsules per hour
100% control of capsule content



pellets

up to 100,000 capsules per hour, two chambers which are alternately filled and emptied



tablets

60,000-100,000 capsules per hour, depending on the number of tablets to be dosed per capsule and on the size and shape



Other potential combinations of capsule products:

- Powder
- Liquid
- Up to three pellet types with different active ingredients
- Up to three tablet types with different active ingredients
- Micro-tablets
- Capsules
- Combination: pellets, capsule, and tablet
- Combination: powder, tablet, and pellets
- Combination: tablet and two pellet types with different active ingredients
- Combination: powder and two tablet types with different active ingredients
- Combination: powder and liquid.

Capsule size: 00, 0, 1, 2, 3, 4.

Capsule types: hard gelatine capsules, HPMC.

You can order both small and large batches manufactured in compliance with the highest quality standards and with short turnaround times.

Pilot Plant

Within the Research and Development Division, 2017 saw the completion of the Pilot Plant, an investment in R&D pilot production. This project received funding from European Union structural funds. Pilot production of previously developed prototypes is an essential stage of the R&D process and a necessary precondition for the successful completion of development work and, in the long-term, for obtaining a marketing authorisation permit and for production scale-up. Extending our organisational structure to include the specialist pilot drug candidate manufacturing area will translate into a range of benefits, including:

- fast and flexible implementation of R&D projects by making them independent of current production schedule
- efficient identification, optimisation, and validation of critical manufacturing parameters defined at the laboratory R&D stage
- development of guidelines for manufacturing and quality control processes
- supply of products for conducting clinical studies.

The new technologies which have been acquired for the Pilot Plant, including a multilayer tablet press, a Hot Melt Extrusion (HME) machine, and a fluid granulator, will also create more opportunities for R&D activities related to next-generation products. Introducing pilot production lines involving innovative multilayer tableting or extrusion techniques will enable the development of semi-products and final forms of medicinal products with the added value necessary for securing a competitive advantage, which is difficult to accomplish with standard pharmaceutical processes.

The Pilot Plant was formally inaugurated in April 2018.



Fundusze Europejskie
Inteligentny Rozwój

Unia Europejska
Europejski Fundusz
Rozwoju Regionalnego



ADAMED
For the Family



Business development



International expansion

Adamed started its international expansion in 2003. As of today, its products are available in over 70 countries worldwide, including in Europe, the Middle East, Asia, Africa, Latin America, and Oceania.

Adamed Pharma has 9 representative offices. A consistently implemented development strategy based on innovation and international expansion has made the company a renowned global brand. For many years, Adamed Pharma has recorded a steady increase in the volume and value of its product sales. International operations currently account for a third of the overall business, and the development plans anticipate a further increase in this share to 55%.



● Head Office: Pieńków near Warsaw, Poland

Representative offices: 

Investment in Asia



Adamed Pharma is a 100% shareholder of Davipharm, one of the fastest growing pharmaceutical companies in Vietnam. Adamed Pharma has thus become the sole owner of the Vietnamese company, one of the fastest growing pharmaceutical companies in this part of Asia. To date, Adamed's capital involvement in Vietnam has amounted to nearly USD 60 million. This is one of the largest Polish direct investments in this part of the world.

Currently, foreign markets account for nearly 40 percent of Adamed Pharma's revenue. In the medium term, the objective is to achieve a 50:50 ratio, while in the ten-year horizon it is foreign revenue that is expected to predominate in the company's overall revenue. Owing to the Vietnamese investment, Adamed Pharma will further expand its operations in Asia and export its drug products to highly regulated markets. The acquisition of a 100 percent stake in Davipharm not only underscores the importance of the Vietnamese market in the company's development plans, but is also a testament to Adamed's strategy, a key element of which is international expansion.





Out-licensing

The Licence-Out team is a group of experienced professionals responsible for the sale of Adamed products worldwide. We are open to different business models, including licensing, distribution, co-development of new products, and contract manufacturing. We are also responsible for the sale of licenses to third parties. We provide full support within the scope of regulatory affairs and intellectual property, new product launch strategies, and open cooperation. All this is to ensure the successful implementation of new products with minimum risk and at competitive prices. We provide our business partners with registration dossiers for ready-made drugs, prepared in the CTD format, which meet the strictest requirements set out in the GMP and stipulated by regulatory agencies around the world. Thanks to the License-out team's experience, we can offer the highest quality of partnership based on a win-win strategy.

Representative offices in Eastern Markets

Since 2005, Adamed has been very active in the Commonwealth of Independent States through its representative offices in Kiev, Moscow, and Almaty. Our long-standing presence in Eastern Europe has made us familiar with the needs of patients in this region. To meet their expectations, we are continually enriching our portfolio with new Rx and OTC products in nearly all therapeutic areas. We make use of novel promotion and sales management tools such as a CRM system, databases, market monitoring, and geo-marketing. Adamed's most important achievements in the eastern region include over 100 products on the market, a dozen new launches per year, and a strategy for maintaining high growth dynamics.

In 2014, Adamed was rated among the fifty best pharmaceutical employers in Ukraine. It was also ranked the country's 10th fastest-growing company.

In-licensing

The In-Licensing Department is engaged in obtaining new product offers, which are then gradually added to Adamed's portfolio. The department is responsible for short-listing the available offers, conducting successful negotiations, and signing agreements with selected contractors. The company is in close contact with all the largest generics companies in Europe and beyond. This allows us to continuously survey the pharmaceutical market to spot the available molecules and expiring patents and to identify new business opportunities.

License-out offer

We are always vigilant and respond to changes in both domestic and foreign markets. We are constantly searching for new markets where our products could make their mark.

GYNAECOLOGY & UROLOGY

- **FINASTERIDE + TADALAFIL**, 5mg/5mg, tablets **NEW**
- **PROGESTERONE**, 50mg, 100mg, 200mg, vaginal tablets
- **SILDENAFIL** 25mg, 50mg, 100mg, coated tablets
- **SOLIFENACIN + TAMSULOSIN OCAS®** 6mg/0,4mg, extended release tablets
- **TAMSULOSIN OCAS®** 0,4 mg, extended release tablets
- **TRANEXAMIC ACID** 1000mg; 500mg, tablets **NEW**

CARDIOLOGY

- **AMLODIPINE** 5mg; 10mg, tabletki
- **CANDESARTAN + AMLODIPINE** 8mg/5mg; 8mg/10mg; 16mg/5mg; 16mg/10mg, capsules **NEW**
- **CANDESARTAN + AMLODIPINE + HCTZ** **NEW**
16mg/5mg/12,5mg, 16mg/10mg/12,5mg
- **CILOSTAZOL** 50mg; 100mg, tablets
- **DABIGATRAN** 75mg; 110mg; 150mg, capsules **NEW**
- **EPLERENONE** 25mg; 50mg, coated tablets
- **EZETIMIBE** 10mg, tablets
- **EZETIMIBE + ROSUVASTATIN**
10mg/5mg; 10mg/10mg; 10mg/15mg; 10mg/20mg;
10mg/30mg; 10mg/40mg, tablets **NEW**
- **PERINDOPRIL TERT-BUTYLAMINE + AMLODIPINE**
4mg/5mg; 4mg/10mg; 8mg/5mg; 8mg/10mg, tablets

- **RAMIPRIL + AMLODIPINE** 2,5mg/5mg; 5mg/5mg; 5mg/10mg; 10mg/5mg; 10mg/10mg, capsules
- **RAMIPRIL + AMLODIPINE BESYLATE + HCTZ**
5mg/5mg/25mg; 10mg/5mg/25mg; 5mg/5mg/12,5mg;
10mg/10mg/25mg, capsules
- **RAMIPRIL + BISOPROLOL** 2,5mg/1,25mg;
2,5mg/2,5mg; 5mg/2,5mg; 5mg/5mg; 10mg/5mg;
10mg/10mg, capsules **NEW**
- **RANOLAZINE** 375mg; 500mg; 750mg,
extended release tablets **NEW**
- **RIVAROXABAN** 2,5mg; 10mg; 15mg; 20mg,
coated tablets **NEW**
- **ROSUVASTATIN** 5mg, 10mg, 15mg, 20mg, 30mg, 40mg
coated tablets
- **ROSUVASTATIN + ACETYLSALICYLIC ACID**
5mg/100mg; 10mg/100mg; 20mg/100mg, capsules
- **ROSUVASTATIN + AMLODIPINE** 10mg/5mg;
10mg/10mg; 20mg/5mg; 20mg/10mg, capsules
- **TELMISARTAN + ROSUVASTATIN** (license without supply)
40mg/10mg; 40mg/20mg; 80mg/10mg;
80mg/20mg, coated tablets **NEW**

DIABETOLOGY

- **LINAGLIPTIN**, 5mg, coated tablets **NEW**
- **SITAGLIPTIN** 25mg; 50mg; 100mg, coated tablets
- **SITAGLIPTIN + METFORMIN XR**
50mg/500mg; 50mg/1000mg; 100mg/1000mg;
extended release tablets

ONCOLOGY

- ABIRATERONE 250mg; 500mg, coated tablets
- BORTEZOMIB 3,5mg, vial
- IMATINIB 100mg; 400mg, capsules
- SUNITINIB 12,5mg; 25mg; 37,5mg; 50mg, capsules

CENTRAL NERVOUS SYSTEM

- **B1 + B6 + B12 Vitamin Complex** 150mg/50mg/0,2mg, coated tablets **NEW**
- DULOXETINE 30mg; 60mg, enteric-coated tablets
- MIANSERIN 60mg, coated tablets
- OLANZAPINE 5mg; 10mg, tablets
- OLANZAPINE ODT 5mg; 10mg; 15mg; 20mg, orodispersible tablets
- PREGABALIN 25mg; 50mg; 75mg; 100mg; 150mg; 200mg; 225mg; 300mg, capsules

PULMONOLOGY & ALLERGOLOGY

- LEVOCETIRIZINE 5mg, coated tablets
- LEVOCETIRIZINE 0,5mg/ml, oral solution


OTHER THERAPEUTIC AREAS

- AZITHROMYCIN 250mg; 500mg, coated tablets
- DEXAMETHASONE 4mg; 8mg; 20mg, tablets
- FLUDROCORTISONE 0,1mg, tablets
- NAPROXEN 500mg, enteric-coated tablets
- RISEDRONATE SODIUM 35mg; 75mg, coated tablets

(OTC)

- BIOTIN 10mg, tablets
- CYTISINE 1,5mg, coated tablets
- **CYTISINE 1,5mg, oral solution (spray)** **NEW**
- DROTAVERINE + METAMIZOLE + CAFFEINE 40mg/400mg/60mg; 80mg/400mg/60mg, tablets
- FURAZIDIN 50mg; 100mg, tablets
- HYMECROMONE 400mg, tablets
- **INOSINE PRANOBEX 312,5mg/ml powder for oral suspension** **NEW**
- METAMIZOLE 500mg, tablets
- MINOXIDIL 5%, foam **NEW**
- NAPROXEN SODIUM 220mg, capsules
- SILDENAFIL 25mg; 50mg, coated tablets (also available as Rx) **NEW**
- Tranexamic Acid 500mg, tablets (also available as RX) **NEW**

Adamed's revenues - Export*



* Internal data.

Startups

Adamed has actively supported start-ups in Poland since 2015. To that end, the company has established a venture capital arm through which – beyond simply pursuing investment opportunities – it has been involved in several initiatives providing assistance to start-ups taking their very first steps in product development and developing their commercial operations. Adamed has been involved in a series of acceleration programmes for budding technological companies, acting as a partner to support projects related to the healthcare sector. In recent years, these have included:

→ **MIT Enterprise Forum Poland and MIT Enterprise Forum CEE** – the programs are based on the know-how of the world's most renowned technical university, the Massachusetts Institute of Technology. As a partner to the Health path, Adamed provides the program participants with, among other things, support from experienced mentors, access to inhouse laboratory facilities, possibility to deploy pilot programs and help in building business models. Selected editions of the program were co-financed under the ScaleUp program of the Polish Agency for Enterprise Development (PARP), which made it possible to support startups with up to PLN 200,000. Adamed has been a partner to each of the editions of both programs carried out to date.

→ **Scale-up Champions**, an international initiative offering support for deep tech digital startups from all over Europe. It helps startups to venture into international markets, start collaborations with corporations and investors, and as a result, scale up their business.

→ **MedBiz Innovations** – mentoring program created for students of various faculties, including medical studies, to jointly create innovative solutions. Teams of students work on ideas for a product or service that combine modern technology, medicine and business. Projects with the highest potential for commercial application are further developed under supervision of experienced representatives of the MedTech sector.

→ **Science Startup** – an accelerator program implemented by the Subcarpathian Innovation Center aimed at shaping pro-innovative and entrepreneurial attitudes and supporting Subcarpathian scientists in setting up academic startups. Science Startup offers mentoring, training sessions and networking activities to scientific teams.

→ **SmartUp Lab 2022** – educational and incubation program organized by the Medical University of Łódź. The program targets young innovators interested in developing creative solutions: students, PhD students, graduates, scientists and entrepreneurs who form interdisciplinary teams developing ideas and products under subject-specific mentoring.



Enterprise Forum
CEE



MedBiz
Innovations Program

2022

Smart-Up Lab



SCALE-UP
CHAMPIONS


ADAMED
For the Family



Corporate Social Responsibility



CSR Strategy

Mission

We respond to the key challenges of modern medicine.



A responsible Partner for the Polish economy

We have a global impact on economic and social development.



A responsible Manufacturer

We ensure the highest product quality, protect the natural environment, and follow best practices.



A responsible Employer

We shape a friendly and engaging work environment.



Innovation

We create new solutions in order to address the needs of patients with lifestyle diseases.

Values



Openness and innovation



Quality



Mutual respect



Operational excellence



Flexibility and speed of action

Ethics

Adamed's success comes not only from our performance and business agility, but most of all from our reputation as an ethical and trustworthy company. With us, operating within the law is a given. Still, we know that it takes more than that to build the company of our dreams. In addition to legal regulations, at Adamed we respect good

practices, industry standards, and the universal values, social norms, and ethical principles that foster a reliable and trustworthy business environment. We expect the same from our contractors and business partners.

Adamed Pharma's community programmes – for the common good

Through its social programmes, Adamed supports the development of science in Poland, educates the public, and contributes to health promotion and disease prevention. The aim of our activities is to reach as many recipients as possible and to significantly influence positive changes.

Adamed for Family

In 2022, the **Adamed for Family** campaign took place, as part of which 2153 free medical examinations and consultations were carried out in 6 Polish cities. An additional activity as part of the initiative was to check the health of Poles, and the results were presented in an extensive report with experts' comments.





Adamed for Seniors

The **Adamed for Seniors** programme is our answer to the challenges faced by seniors in the 21st century and aims to engage that age group to lead a more active lifestyle.


Adamed supports senior citizens, helping to educate and encourage them to be more active and to work on their well-being and physical fitness. We also carry out activities promoting health prevention to detect health problems earlier and to challenge the stereotypes associated with senior citizens' everyday lives. We want older people to enjoy a healthy life for as long as possible, as well as to pursue and develop their interests.

Adamed dla Seniora covers three key areas of activity:

- Partnership-based involvement in events organized for senior citizens, not only by providing financial support for key events in Poland, but above all by offering medical advice and by organising free preventive medical testing.
- Strategic partnerships with the Nationwide Association of Universities of the Third Age, the Manko Association, and the National Institute for Seniors, through which we have helped educate senior citizens across Poland.
- Nationwide competitions.



www.adameddlaseniora.pl



Find Yourself (Odnaleźć siebie)

The **Find Yourself** programme is intended to raise awareness and to expand the knowledge about nervous system disorders and diseases among the general public, as well as to overcome social barriers related to the treatment of psychological and neurological symptoms. The concept behind the programme is to foster awareness of the importance of diagnostics and early treatment of mental and neurological disorders. It is also intended to disseminate knowledge about disorders such as schizophrenia, bipolar disorder, depression, epilepsy, Alzheimer's disease, and Parkinson's disease.



www.odnalezcziebie.pl



New at Heart (Serce na nowo)

As part of its education and information programme, Adamed has worked to improve the social and professional lives of those with cardiovascular diseases since 2008. The programme is designed to challenge stereotypes and convince the public that those with cardiovascular disease can lead an active lifestyle and have satisfying careers. It offers additional insights on preventing cardiovascular disease and living a socially and professionally active life, despite certain health problems.



serce **na nowo**

www.sercenanowo.pl

Deep Breath (Głęboki Oddech)

Deep Breath is Adamed's nationwide preventative healthcare and awareness-raising programme designed to increase public awareness of the causes and consequences of respiratory diseases, such as asthma, chronic obstructive pulmonary disease (COPD), croup syndrome, and allergies.



www.glebokioddech.pl


ADAMED
For the Family

Adamed foundation



The Adamed Foundation was established to support research and development and scientific and educational activities in the field of natural sciences. The Foundation promotes cooperation in the scientific community, as well as the pharmaceutical, medical, and biotechnology industries. It strengthens cooperation with entities with similar roles and objectives operating in Poland and abroad. One of the Foundation's key tasks is to support young talented people.



ADAMED SmartUP

ADAMED SmartUP is an innovative education programme for secondary school students. The aim of the programme is to promote natural and life sciences among young people in Poland and to support the educational development of the most talented students. The basis of the initiative is the www.adamedsmartup.pl on-line platform and a scholarship program for adolescents aged 14–18 years. The programme was conducted under the honorary auspices of the Ministry of Education and Science, the National Centre for Research and Development, the Warsaw University of Technology, the Polish Academy of Sciences, the Warsaw University of Life Sciences, and many other renowned universities in Poland.



Adamed Expert Fundacja

The Adamed Foundation has long been involved in supporting science and working with the scientific community, recognizing science as the most important vehicle for changing the world for the better.

In 2020, the Foundation launched the Adamed Expert Foundation programme, which is aimed to create and disseminate reliable, expert information on medicine and health prevention.

The programme is directed by the Adamed Expert Foundation Scientific Council made up of eminent members of the Polish scientific community.



ADAMED SmartUP

Platforma Edukacyjna:



Over **200** educational videos

Social Media:



@adamed_smartup



/ADAMEDSmartUP



@ADAMEDSmartUP

9 years of popularization of science:



about **7000**
registered participants

450
programme alumni



90
main prize winners

24
scholarships awarded

Spain:



2 editions, almost **200** students

Roadshow – demonstration lessons in Polish schools:



ADAMED SmartUP Academy:



over **2 000**
participants of free science
workshops



Adamed Pharma S.A.
Pieńków, ul. Mariana Adamkiewicza 6a,
05-152 Czosnów, Polska
tel.: +48 22 732 77 00
e-mail: adamed@adamed.com
www.adamed.com



